Legend Biotech
LEGN
190 hedge funds and large institutions have $1.74B invested in Legend Biotech in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 80 increasing their positions, 49 reducing their positions, and 40 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 49
28% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $9.22M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.5% more ownership
Funds ownership: 47.43% → 51.93% (+4.5%)
5% less funds holding
Funds holding: 200 → 190 (-10)
9% less capital invested
Capital invested by funds: $1.91B → $1.74B (-$170M)
20% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FBIL
First Beijing Investment Ltd
Hong Kong
|
+$43.8M |
| 2 |
DM
Deerfield Management
New York
|
+$33.5M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$30.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.2M |
| 5 |
Two Sigma Investments
New York
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$33M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$28.2M |
| 3 |
Goldman Sachs
New York
|
-$13.5M |
| 4 |
JP Morgan Chase
New York
|
-$12.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.94M |
LEGN Hedge Fund Activity: Q1 2026 in Review
190 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2026, worth a combined $1.74B — down 8.9% from $1.91B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of LEGN and 32 opened new positions — a net loss of 8 holders — while 49 trimmed existing stakes and 80 added.
The largest buyer was First Beijing Investment Ltd, opening a new position worth an estimated $43.8M. The largest seller was AllianceBernstein, exiting entirely with an estimated $33M sold.
- 190 institutional investors held Legend Biotech (LEGN) as of Q1 2026, down from 200 in Q4 2025.
- Funds reported $1.74B of Legend Biotech stock for Q1 2026, down 8.9% quarter-over-quarter.
- 32 funds opened new Legend Biotech positions in Q1 2026 and 40 closed out, a net change of -8 holders.
- The largest Legend Biotech buyer in Q1 2026 was First Beijing Investment Ltd, an estimated $43.8M added.
- The largest Legend Biotech seller in Q1 2026 was AllianceBernstein, an estimated $33M sold.
Based on aggregated 13F filings for Q1 2026.